Clearmind Medicine (CMND) Competitors $1.40 +0.04 (+2.94%) (As of 11/4/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends CMND vs. RNAZ, IMNN, ABVC, VIRX, ATHE, CYCN, CANF, NKGN, PULM, and OBSVShould you be buying Clearmind Medicine stock or one of its competitors? The main competitors of Clearmind Medicine include TransCode Therapeutics (RNAZ), Imunon (IMNN), ABVC BioPharma (ABVC), Viracta Therapeutics (VIRX), Alterity Therapeutics (ATHE), Cyclerion Therapeutics (CYCN), Can-Fite BioPharma (CANF), NKGen Biotech (NKGN), Pulmatrix (PULM), and ObsEva (OBSV). These companies are all part of the "pharmaceutical products" industry. Clearmind Medicine vs. TransCode Therapeutics Imunon ABVC BioPharma Viracta Therapeutics Alterity Therapeutics Cyclerion Therapeutics Can-Fite BioPharma NKGen Biotech Pulmatrix ObsEva TransCode Therapeutics (NASDAQ:RNAZ) and Clearmind Medicine (NASDAQ:CMND) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their community ranking, valuation, dividends, earnings, media sentiment, analyst recommendations, profitability, institutional ownership and risk. Does the MarketBeat Community favor RNAZ or CMND? TransCode Therapeutics received 11 more outperform votes than Clearmind Medicine when rated by MarketBeat users. CompanyUnderperformOutperformTransCode TherapeuticsOutperform Votes1191.67% Underperform Votes18.33%Clearmind MedicineN/AN/A Do insiders & institutionals believe in RNAZ or CMND? 96.1% of Clearmind Medicine shares are held by institutional investors. 0.2% of TransCode Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Do analysts recommend RNAZ or CMND? TransCode Therapeutics presently has a consensus target price of $3.00, indicating a potential upside of 482.52%. Given TransCode Therapeutics' higher probable upside, analysts clearly believe TransCode Therapeutics is more favorable than Clearmind Medicine.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TransCode Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Clearmind Medicine 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/A Which has preferable valuation and earnings, RNAZ or CMND? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTransCode TherapeuticsN/AN/A-$18.55MN/AN/AClearmind MedicineN/AN/A-$8.62MN/AN/A Which has more volatility & risk, RNAZ or CMND? TransCode Therapeutics has a beta of 0.65, indicating that its share price is 35% less volatile than the S&P 500. Comparatively, Clearmind Medicine has a beta of 1.26, indicating that its share price is 26% more volatile than the S&P 500. Is RNAZ or CMND more profitable? Clearmind Medicine's return on equity of -238.73% beat TransCode Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets TransCode TherapeuticsN/A -597.48% -260.31% Clearmind Medicine N/A -238.73%-102.10% Does the media prefer RNAZ or CMND? In the previous week, TransCode Therapeutics' average media sentiment score of 0.00 equaled Clearmind Medicine'saverage media sentiment score. Company Overall Sentiment TransCode Therapeutics Neutral Clearmind Medicine Neutral SummaryClearmind Medicine beats TransCode Therapeutics on 5 of the 9 factors compared between the two stocks. Ad Porter & CompanyRigged election? Porter Stansberry’s viral Breaking Point 2024 broadcast has now been by tens of thousands of Americans who finally understand the grim reality of our next election. With November 5 just around the corner, it’s imperative for your financial future that you read Porter’s message below now and then watch Breaking Point before it’s too late. Watch this video, it is being taken down Monday night Get Clearmind Medicine News Delivered to You Automatically Sign up to receive the latest news and ratings for CMND and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CMND vs. The Competition Export to ExcelMetricClearmind MedicinePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.37M$6.76B$5.06B$8.43BDividend YieldN/A7.94%7.52%4.16%P/E RatioN/A12.22131.9616.70Price / SalesN/A271.051,683.8276.34Price / CashN/A46.0937.1533.56Price / Book0.335.274.614.98Net Income-$8.62M$151.58M$115.40M$224.69M7 Day Performance-1.41%0.28%-0.26%1.31%1 Month Performance13.82%14.86%5.74%4.90%1 Year Performance-66.43%36.83%33.81%26.34% Clearmind Medicine Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CMNDClearmind Medicine0.2795 of 5 stars$1.40+2.9%N/A-67.4%$2.37MN/A0.00N/ARNAZTransCode Therapeutics2.244 of 5 stars$0.56-6.1%$3.00+435.4%-96.6%$9.68MN/A0.009IMNNImunon3.3796 of 5 stars$0.96-0.7%$14.00+1,359.9%-7.8%$9.02M$500,000.00-0.5033Upcoming EarningsABVCABVC BioPharmaN/A$0.70-5.0%N/A-43.6%$8.73M$136,396.00-0.4230Gap UpVIRXViracta Therapeutics3.2397 of 5 stars$0.22-5.0%$5.50+2,390.9%-71.5%$8.70MN/A-0.1920Positive NewsGap DownHigh Trading VolumeATHEAlterity Therapeutics2.6589 of 5 stars$1.16+0.5%$4.00+246.3%-51.3%$8.43MN/A0.0010Positive NewsCYCNCyclerion Therapeutics0.8876 of 5 stars$3.04-3.8%N/A+26.1%$8.24M$1.62M0.0030Upcoming EarningsGap UpHigh Trading VolumeCANFCan-Fite BioPharma1.3764 of 5 stars$2.32-3.7%$18.00+675.9%-0.7%$8.21M$667,000.00-1.308News CoverageNKGNNKGen BiotechN/A$0.31-11.2%N/A-91.1%$8.01M$80,000.00-0.06N/AGap UpPULMPulmatrix0.187 of 5 stars$2.18+4.3%N/A+11.5%$7.96M$11.39M-0.7420Analyst ForecastNews CoverageOBSVObsEvaN/AN/AN/AN/A$7.94M$20.11M-0.1150News Coverage Related Companies and Tools Related Companies RNAZ Competitors IMNN Competitors ABVC Competitors VIRX Competitors ATHE Competitors CYCN Competitors CANF Competitors NKGN Competitors PULM Competitors OBSV Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CMND) was last updated on 11/4/2024 by MarketBeat.com Staff From Our Partners2 sentences that change everything you THOUGHT you knew about tradingIf you're like most people, on Friday morning you'll probably follow your set routine: Wake up... eat breakfas...Investing Daily | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredThe centerpiece of Trump’s crypto’s masterplan …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin...Weiss Ratings | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredA Totally New ‘Income Coin’Buckle up… Because this might shatter everything you thought you knew about "income trading." In fact, i...Crypto 101 Media | SponsoredA new way to play the AI boom (act before November 19)There's a new way to play the $15 trillion AI boom. And it's so simple - you can do it right now with as li...Behind the Markets | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Clearmind Medicine Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Clearmind Medicine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
